Neoadjuvant immune checkpoint blockade triggers persistent and systemic Treg activation which blunts therapeutic efficacy against metastatic spread of breast tumors
The clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the neoadjuvant and perioperative setting. However, how neoadjuvant ICB therapy affects the systemic immune landscape and metastatic spread remains to be...
Uloženo v:
| Vydáno v: | Oncoimmunology Ročník 12; číslo 1; s. 2201147 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Taylor & Francis
31.12.2023
Taylor & Francis Group |
| Témata: | |
| ISSN: | 2162-402X, 2162-4011, 2162-402X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the neoadjuvant and perioperative setting. However, how neoadjuvant ICB therapy affects the systemic immune landscape and metastatic spread remains to be established. Tumors promote both local and systemic expansion of regulatory T cells (T
regs
), which are key orchestrators of tumor-induced immunosuppression, contributing to immune evasion, tumor progression and metastasis. T
regs
express inhibitory immune checkpoint molecules and thus may be unintended targets for ICB therapy counteracting its efficacy. Using ICB-refractory models of spontaneous primary and metastatic breast cancer that recapitulate the poor ICB response of breast cancer patients, we observed that combined anti-PD-1 and anti-CTLA-4 therapy inadvertently promotes proliferation and activation of T
regs
in the tumor, tumor-draining lymph node and circulation. Also in breast cancer patients, T
reg
levels were elevated upon ICB. Depletion of T
regs
during neoadjuvant ICB in tumor-bearing mice not only reshaped the intratumoral immune landscape into a state favorable for ICB response but also induced profound and persistent alterations in systemic immunity, characterized by elevated CD8+ T cells and NK cells and durable T cell activation that was maintained after treatment cessation. While depletion of T
regs
in combination with neoadjuvant ICB did not inhibit primary tumor growth, it prolonged metastasis-related survival driven predominantly by CD8+ T cells. This study demonstrates that neoadjuvant ICB therapy of breast cancer can be empowered by simultaneous targeting of T
regs,
extending metastasis-related survival, independent of a primary tumor response. |
|---|---|
| AbstractList | The clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the neoadjuvant and perioperative setting. However, how neoadjuvant ICB therapy affects the systemic immune landscape and metastatic spread remains to be established. Tumors promote both local and systemic expansion of regulatory T cells (T
regs
), which are key orchestrators of tumor-induced immunosuppression, contributing to immune evasion, tumor progression and metastasis. T
regs
express inhibitory immune checkpoint molecules and thus may be unintended targets for ICB therapy counteracting its efficacy. Using ICB-refractory models of spontaneous primary and metastatic breast cancer that recapitulate the poor ICB response of breast cancer patients, we observed that combined anti-PD-1 and anti-CTLA-4 therapy inadvertently promotes proliferation and activation of T
regs
in the tumor, tumor-draining lymph node and circulation. Also in breast cancer patients, T
reg
levels were elevated upon ICB. Depletion of T
regs
during neoadjuvant ICB in tumor-bearing mice not only reshaped the intratumoral immune landscape into a state favorable for ICB response but also induced profound and persistent alterations in systemic immunity, characterized by elevated CD8+ T cells and NK cells and durable T cell activation that was maintained after treatment cessation. While depletion of T
regs
in combination with neoadjuvant ICB did not inhibit primary tumor growth, it prolonged metastasis-related survival driven predominantly by CD8+ T cells. This study demonstrates that neoadjuvant ICB therapy of breast cancer can be empowered by simultaneous targeting of T
regs,
extending metastasis-related survival, independent of a primary tumor response. The clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the neoadjuvant and perioperative setting. However, how neoadjuvant ICB therapy affects the systemic immune landscape and metastatic spread remains to be established. Tumors promote both local and systemic expansion of regulatory T cells (Tregs), which are key orchestrators of tumor-induced immunosuppression, contributing to immune evasion, tumor progression and metastasis. Tregs express inhibitory immune checkpoint molecules and thus may be unintended targets for ICB therapy counteracting its efficacy. Using ICB-refractory models of spontaneous primary and metastatic breast cancer that recapitulate the poor ICB response of breast cancer patients, we observed that combined anti-PD-1 and anti-CTLA-4 therapy inadvertently promotes proliferation and activation of Tregs in the tumor, tumor-draining lymph node and circulation. Also in breast cancer patients, Treg levels were elevated upon ICB. Depletion of Tregs during neoadjuvant ICB in tumor-bearing mice not only reshaped the intratumoral immune landscape into a state favorable for ICB response but also induced profound and persistent alterations in systemic immunity, characterized by elevated CD8+ T cells and NK cells and durable T cell activation that was maintained after treatment cessation. While depletion of Tregs in combination with neoadjuvant ICB did not inhibit primary tumor growth, it prolonged metastasis-related survival driven predominantly by CD8+ T cells. This study demonstrates that neoadjuvant ICB therapy of breast cancer can be empowered by simultaneous targeting of Tregs, extending metastasis-related survival, independent of a primary tumor response. The clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the neoadjuvant and perioperative setting. However, how neoadjuvant ICB therapy affects the systemic immune landscape and metastatic spread remains to be established. Tumors promote both local and systemic expansion of regulatory T cells (Tregs), which are key orchestrators of tumor-induced immunosuppression, contributing to immune evasion, tumor progression and metastasis. Tregs express inhibitory immune checkpoint molecules and thus may be unintended targets for ICB therapy counteracting its efficacy. Using ICB-refractory models of spontaneous primary and metastatic breast cancer that recapitulate the poor ICB response of breast cancer patients, we observed that combined anti-PD-1 and anti-CTLA-4 therapy inadvertently promotes proliferation and activation of Tregs in the tumor, tumor-draining lymph node and circulation. Also in breast cancer patients, Treg levels were elevated upon ICB. Depletion of Tregs during neoadjuvant ICB in tumor-bearing mice not only reshaped the intratumoral immune landscape into a state favorable for ICB response but also induced profound and persistent alterations in systemic immunity, characterized by elevated CD8+ T cells and NK cells and durable T cell activation that was maintained after treatment cessation. While depletion of Tregs in combination with neoadjuvant ICB did not inhibit primary tumor growth, it prolonged metastasis-related survival driven predominantly by CD8+ T cells. This study demonstrates that neoadjuvant ICB therapy of breast cancer can be empowered by simultaneous targeting of Tregs, extending metastasis-related survival, independent of a primary tumor response.The clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the neoadjuvant and perioperative setting. However, how neoadjuvant ICB therapy affects the systemic immune landscape and metastatic spread remains to be established. Tumors promote both local and systemic expansion of regulatory T cells (Tregs), which are key orchestrators of tumor-induced immunosuppression, contributing to immune evasion, tumor progression and metastasis. Tregs express inhibitory immune checkpoint molecules and thus may be unintended targets for ICB therapy counteracting its efficacy. Using ICB-refractory models of spontaneous primary and metastatic breast cancer that recapitulate the poor ICB response of breast cancer patients, we observed that combined anti-PD-1 and anti-CTLA-4 therapy inadvertently promotes proliferation and activation of Tregs in the tumor, tumor-draining lymph node and circulation. Also in breast cancer patients, Treg levels were elevated upon ICB. Depletion of Tregs during neoadjuvant ICB in tumor-bearing mice not only reshaped the intratumoral immune landscape into a state favorable for ICB response but also induced profound and persistent alterations in systemic immunity, characterized by elevated CD8+ T cells and NK cells and durable T cell activation that was maintained after treatment cessation. While depletion of Tregs in combination with neoadjuvant ICB did not inhibit primary tumor growth, it prolonged metastasis-related survival driven predominantly by CD8+ T cells. This study demonstrates that neoadjuvant ICB therapy of breast cancer can be empowered by simultaneous targeting of Tregs, extending metastasis-related survival, independent of a primary tumor response. |
| Author | Kersten, Kelly Spagnuolo, Lorenzo Isaeva, Olga I. Vrijland, Kim Hau, Cheei-Sing Kaldenbach, Daphne Garner, Hannah Kos, Kevin Kok, Marleen Raeven, Elisabeth A.M. Blomberg, Olga S. Klarenbeek, Sjoerd Duits, Danique E.M. Wellenstein, Max D. de Visser, Karin E. Bakker, Noor |
| Author_xml | – sequence: 1 givenname: Olga S. surname: Blomberg fullname: Blomberg, Olga S. organization: Leiden University Medical Center – sequence: 2 givenname: Kevin surname: Kos fullname: Kos, Kevin organization: Leiden University Medical Center – sequence: 3 givenname: Lorenzo surname: Spagnuolo fullname: Spagnuolo, Lorenzo organization: Oncode Institute – sequence: 4 givenname: Olga I. surname: Isaeva fullname: Isaeva, Olga I. organization: Netherlands Cancer Institute – sequence: 5 givenname: Hannah surname: Garner fullname: Garner, Hannah organization: Oncode Institute – sequence: 6 givenname: Max D. surname: Wellenstein fullname: Wellenstein, Max D. organization: Leiden University Medical Center – sequence: 7 givenname: Noor surname: Bakker fullname: Bakker, Noor organization: Leiden University Medical Center – sequence: 8 givenname: Danique E.M. surname: Duits fullname: Duits, Danique E.M. organization: Leiden University Medical Center – sequence: 9 givenname: Kelly surname: Kersten fullname: Kersten, Kelly organization: Netherlands Cancer Institute – sequence: 10 givenname: Sjoerd surname: Klarenbeek fullname: Klarenbeek, Sjoerd organization: Netherlands Cancer Institute – sequence: 11 givenname: Cheei-Sing surname: Hau fullname: Hau, Cheei-Sing organization: Oncode Institute – sequence: 12 givenname: Daphne surname: Kaldenbach fullname: Kaldenbach, Daphne organization: Oncode Institute – sequence: 13 givenname: Elisabeth A.M. surname: Raeven fullname: Raeven, Elisabeth A.M. organization: Oncode Institute – sequence: 14 givenname: Kim surname: Vrijland fullname: Vrijland, Kim organization: Oncode Institute – sequence: 15 givenname: Marleen surname: Kok fullname: Kok, Marleen organization: Netherlands Cancer Institute – sequence: 16 givenname: Karin E. orcidid: 0000-0002-0293-868X surname: de Visser fullname: de Visser, Karin E. email: k.d.visser@nki.nl organization: Leiden University Medical Center |
| BookMark | eNpVUk1v1DAUjFCRKKU_AclHLrs4dpyPE6CKQqUKLkXiZj3bL1lvEzvYzlb7f_ihOOwiUR_s0Zt54yd7XhcXzjssircl3Za0pe9ZWbOKsp9bRhnfMkbLsmpeFJdrfbMSF__hV8V1jHuaV01FzbvL4vc39GD2ywFcInaaFodE71A_zt7mihq9fgSDJAU7DBgimfNmY8JMgjMkHjOerCYPAQcCOtkDJOsdedpZvcv9i0uRpB0GmHFJWYh9bzXoI4EBrIuJTJggJli5OAcEQ3xPVAaZS8vkQ3xTvOxhjHh9Pq-KH7efH26-bu6_f7m7-XS_Mbxu0kYZjabnWkEtmO5qJTpjmrbigmpWYt9iCVVfdaYyTVXlR-CAwoiWZjGFquNXxd3J13jYyznYCcJRerDyb8GHQULIc44oVS1qpLw2RolKtKoFrlS-BzjvoC5V9vpw8poXNWGezKUA4zPT54yzOzn4gyzXH-yaNju8OzsE_2vBmORko8ZxBId-iZK1VIhStExk6ceT1LrehwmefBiNTHAcfegDOG2j5CWVa2Lkv8TINTHynBj-B1NWvOI |
| ContentType | Journal Article |
| Copyright | 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023 The Author(s) |
| Copyright_xml | – notice: 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023 – notice: 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. – notice: 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023 The Author(s) |
| DBID | 0YH 7X8 5PM DOA |
| DOI | 10.1080/2162402X.2023.2201147 |
| DatabaseName | Taylor & Francis Open Access MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | O. S. BLOMBERG ET AL |
| EISSN | 2162-402X |
| ExternalDocumentID | oai_doaj_org_article_b656e036ddb5458b8a3bb50ca339a61b PMC10114978 2201147 |
| Genre | Research Article |
| GrantInformation_xml | – fundername: KWF/Oncode consortium grantid: 14339 – fundername: Ministry of Health – fundername: Swiss National Science Foundation grantid: P2FRP3_171794 – fundername: NWO Oncology Graduate School Amsterdam Diamond Program – fundername: F. Hoffmann-La Roche – fundername: Oncode Institute – fundername: BMS-International Immuno-Oncology Network grantid: NKI2015-7710 |
| GroupedDBID | 00X 0YH 53G AAKDD ABUPF ACGFS ADBBV ADCVX AENEX AIJEM ALMA_UNASSIGNED_HOLDINGS AOIJS AQTUD BABNJ BLEHA CCCUG DGEBU DGFLZ EBS EMOBN EUPTU GROUPED_DOAJ H13 HYE KRBQP KSSTO KTTOD KWAYT KYCEM LJTGL M4Z O9- OK1 RPM TDBHL TFL TFW 7X8 5PM |
| ID | FETCH-LOGICAL-d367t-bdcedf3cba652c96b59dd784350c21ef8e1a4f49d4d7440003ae5d5802c90a493 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 15 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000972127800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2162-402X 2162-4011 |
| IngestDate | Fri Oct 03 12:50:38 EDT 2025 Tue Nov 04 02:06:37 EST 2025 Wed Oct 01 14:07:36 EDT 2025 Mon Oct 20 23:46:48 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | open-access: http://creativecommons.org/licenses/by/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-d367t-bdcedf3cba652c96b59dd784350c21ef8e1a4f49d4d7440003ae5d5802c90a493 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally, listed in alphabetical order. |
| ORCID | 0000-0002-0293-868X |
| OpenAccessLink | https://doaj.org/article/b656e036ddb5458b8a3bb50ca339a61b |
| PQID | 2805515825 |
| PQPubID | 23479 |
| ParticipantIDs | informaworld_taylorfrancis_310_1080_2162402X_2023_2201147 doaj_primary_oai_doaj_org_article_b656e036ddb5458b8a3bb50ca339a61b proquest_miscellaneous_2805515825 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10114978 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-12-31 |
| PublicationDateYYYYMMDD | 2023-12-31 |
| PublicationDate_xml | – month: 12 year: 2023 text: 2023-12-31 day: 31 |
| PublicationDecade | 2020 |
| PublicationTitle | Oncoimmunology |
| PublicationYear | 2023 |
| Publisher | Taylor & Francis Taylor & Francis Group |
| Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Group |
| SSID | ssj0000605639 |
| Score | 2.4178426 |
| Snippet | The clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the... |
| SourceID | doaj pubmedcentral proquest informaworld |
| SourceType | Open Website Open Access Repository Aggregation Database Publisher |
| StartPage | 2201147 |
| SubjectTerms | Breast cancer metastasis myeloid cells neoadjuvant immune checkpoint blockade Original Research regulatory T cells resistance mechanisms |
| SummonAdditionalLinks | – databaseName: Taylor & Francis Open Access dbid: 0YH link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9QwDI5gAYkLb8TwUpC4dmmbtE2OgFjtacRhkYZTlDTuTFltO2pT0P4ffih220FTJE5wqTRJW1ljp_6c2J8Ze4vj4EHKKJNSRxISEWnt6IIRrnUCw1w_Npso1mu12ejPczZhP6dVUgxdTUQR47eaFrd1_SEj7l2a5HQmsDml1t-nKbkwWdxkt1IMTSirK_56_nubJUa4jk74ULvzt6dnxv4_-EoXqHOZM3nkhM7u_wfxH7B7MwLl7yeTechuQPOI3Zl6Ul4_Zj_X0Fr_bUCEHXhN1SPAUbHl5b6tccSh87u0HnjAsH6L2JHvaccNbQUnUSQ-UUPXJb_oYMupbGLa9OU_dnW5w-eHJvT8qOyLA7FY2PKa262tEa3yKwiWCp1wrt8jqPW8rbij7PnAw3DVdv0T9uXs08XH82hu5RB5kRchcvi_-UqUzuZZWurcZdr7QiFWi8s0gUpBYmUltZeeGAvxU2Mh85mK8ebYSi2espOmbeAZ484hYlMuhkTlMk9jqx3eowoQcaWVL1fsA6nS7Ce2DkP82eNA223NvByNQxgL6Ly9d3Ry6JQVzqEsVght88StmD42BBPG7ZNq6nViRDITqx5UaUiVZlblir05WI3BtUoHMLaBduhNqmIEqBkG5SumFua0kHY509S7kfU7oZdjzP_8H0R7we7Sz4mo8iU7Cd0Ar9jt8nuo--71uHJ-AW2uIGU priority: 102 providerName: Taylor & Francis |
| Title | Neoadjuvant immune checkpoint blockade triggers persistent and systemic Treg activation which blunts therapeutic efficacy against metastatic spread of breast tumors |
| URI | https://www.tandfonline.com/doi/abs/10.1080/2162402X.2023.2201147 https://www.proquest.com/docview/2805515825 https://pubmed.ncbi.nlm.nih.gov/PMC10114978 https://doaj.org/article/b656e036ddb5458b8a3bb50ca339a61b |
| Volume | 12 |
| WOSCitedRecordID | wos000972127800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2162-402X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000605639 issn: 2162-402X databaseCode: DOA dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAWR databaseName: Taylor & Francis Journals Complete customDbUrl: eissn: 2162-402X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000605639 issn: 2162-402X databaseCode: TFW dateStart: 20180102 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor & Francis Journals Complete customDbUrl: eissn: 2162-402X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000605639 issn: 2162-402X databaseCode: TFW dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 2162-402X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000605639 issn: 2162-402X databaseCode: 0YH dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgBRIXxFOUx8pIXLPrxE5iHwFR7aniUEQ5RX6lDatNqsZZtP-HH8pMnEoNFy5cfLCdxM6M7W9szzeEfIB877wQSS6ESoRPeaKUwQQsXG04mLluDDZRrlZys1FfT0J94Z2wSA8cf9ylAcDhYZp1zuAZj5GaG5MzqzlXukgNzr6Aek6MqTgHw8LO1dFlR7LLLC3wIGFzgfHCLzJc98aQKvjBv2hKZ2BzflXyZO1ZPiGPJ9BIP8bGPiX3fPuMPIxhJO-ek98r32n3cwBQHGiDDh-egizs9b5rIMfAenWtnacBLPEtwD26x00yEC8U6tbRyObcWLo--C1FT4e4T0t_7Rq7g-eHNvT0xFOLeiSe0PaO6q1uAGDSGx80-iZBWb8HHOpoV1ODF94DDcNNd-hfkG_LL-vPV8kUfSFxvChDYqDPrubW6CLPrCpMrpwrJcArZrPU19KnWtRCOeGQZBBmB-1zl0sGlZkWir8kZ23X-leEGgMgSxrmU1mIImNaGagjS89ZraSzC_IJxVDtI8FGhZTXYwYoQjUpQvUvRVgQdSrEKow7HnUMT1LxdOJCPepBhXpQTXqwIO-PEq9geOGZiW59N_RVJhlgyhzs6AWRM1WYtXZe0ja7kag7xZeDmf76f_TvDXmETY4kk2_JWTgM_h15YG9D0x_OyX324wrSciPPx6EA6Xr5_Q9O-RNE |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaggMqlPKsu5WEkrilJ7CT2ERCrIsqeFrE3y46d3VA1WSVOUf8PP5SZJIs2SJzgkoOdRFZmnPlmPPMNIW9g3FnHeZBwLgPuIhZIafACHq42DNxc2zebyBYLsVrJ_VoYTKtEH7oYiCL6fzVubgxG71Li3sZRiocCqzPs_X0Wow3j2W1yJwFbi2l9y_m333GWEPA6WOFd8c7fnh4p-_8gLJ3AzmnS5J4Vmj_4H-t_SI5GDErfDUrziNxy1WNyb-hKefOE_Fy4WtvvHWBsT0usH3EURJtfbusSRgyYv0ttHfXg2K8BPdItxtxAW2AS1kQHcugyp8vGrSkWTgxhX_pjU-YbeL6rfEv3Cr-oQx4Lnd9QvdYl4FV65bzGUieYa7cAay2tC2owf95T313VTfuUfJ1_XH44D8ZmDoFlaeYDAx_OFiw3Ok3iXKYmkdZmAtBamMeRK4SLNC-4tNwiZyH8bLRLbCJCuDnUXLJjclDVlTsh1BjAbMKELhIpT-NQSwP3iMyxsJDC5jPyHmWptgNfh0IG7X6gbtZq3JDKAJB1YL6tNXh2aIRmxsBaNGNSp5GZEbmvCcr3AZRi6HaiWDRSq-5EqVCUahTljLzeqY2C3YpHMLpyddeqWIQAURNwy2dETPRpstrpTFVuet7vCF8OXv-zf1jaK3J4vvxyoS4-LT6fkvs4NdBWPicHvuncC3I3v_Zl27zst9Ev72Ikjw |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj5wwDI7a7UO99F3t9JlKvbIFEiA59jVq1Wq0h6k6tyghYYauFhCErfb_9IfWBqYaKvXUXjgkgCzs4M-J_ZmQVzDurOM8SDiXAXcRC6Q0eIEIVxsGYa4dmk1kq5XYbOTplE3YTWmVGEMXI1HE8K_Gxd3YYp8R9zqOUjwT2Jxg6--TGF0Yz66SawM5Fpj0evnt9zZLCHAdnPC-dudvT0-M_X_wlc5Q5zxn8sAJLe_8B_HvktsTAqVvRpO5R6646j65MfakvHxAfq5cre33HhC2pyVWjzgKis3PmrqEEQPO70xbRz2E9VvAjrTBHTewFZgEkehIDV3mdN26LcWyiXHTl_7YlfkOnu8r39GDsi_qkMVC55dUb3UJaJWeO6-x0AnmugZAraV1QQ1mz3vq-_O67R6Sr8sP63cfg6mVQ2BZmvnAwHezBcuNTpM4l6lJpLWZAKwW5nHkCuEizQsuLbfIWAi_Gu0Sm4gQbg41l-wROarqyh0TagwgNmFCF4mUp3GopYF7ROZYWEhh8wV5i6pUzcjWoZA_exio262alqMyAGMdOG9rDZ4cGqGZMSCLZkzqNDILIg8NQflh-6QYe50oFk3EqntVKlSlmlS5IC_3VqNgreIBjK5c3XcqFiEA1ASC8gURM3OaSTufqcrdwPod4csh5n_8D6K9IDdP3y_Vl0-rz0_ILZwZOSufkiPf9u4ZuZ5f-LJrnw-L6BdL8CMz |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neoadjuvant+immune+checkpoint+blockade+triggers+persistent+and+systemic+Treg+activation+which+blunts+therapeutic+efficacy+against+metastatic+spread+of+breast+tumors&rft.jtitle=Oncoimmunology&rft.au=Blomberg%2C+Olga+S.&rft.au=Kos%2C+Kevin&rft.au=Spagnuolo%2C+Lorenzo&rft.au=Isaeva%2C+Olga+I.&rft.date=2023-12-31&rft.pub=Taylor+%26+Francis&rft.issn=2162-4011&rft.eissn=2162-402X&rft.volume=12&rft.issue=1&rft_id=info:doi/10.1080%2F2162402X.2023.2201147&rft.externalDocID=PMC10114978 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2162-402X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2162-402X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2162-402X&client=summon |